Pelubiprofen

Pelubiprofen
Clinical data
Trade names	Pelubi
ATC code	None;
Legal status
Legal status	Rx in several countries;
Identifiers
	IUPAC name 2-[4-[(E)-(2-Oxocyclohexylidene)methyl]phenyl]propanoic acid;
CAS Number	69956-77-0;
PubChem CID	5282203;
DrugBank	DB12150;
UNII	1619C79FVJ;
CompTox Dashboard (EPA)	DTXSID2048795 ;
Chemical and physical data
Formula	C16H18O3
Molar mass	258.317 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C1=CC=C(C=C1)/C=C/2\CCCCC2=O)C(=O)O;
	InChI InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+; Key:AUZUGWXLBGZUPP-GXDHUFHOSA-N;

Pelubiprofen is a nonsteroidal anti-inflammatory drug of the profen class used to treat back pain and osteoarthritis.^[1]

Pelubiprofen was developed in South Korea by Daewon Pharmaceuticals and it is marketed in Korea and Russia,^[2] among other countries.

Research

Pelubiprofen is being studied for use in combination with eperisone.^[3]

Because pelubiprofen has low water solubility, development of salt formulations with better solubility are being studied.^[4]

Synthesis

Pelubiprofen can be prepared by the reaction of 1-(1-piperidino)cyclohexene (1) with ethyl 2-(4-formylphenyl)propanoate (2).^[5]^[6]^[7]^[8]^[9]^[10]^[11]

Synthesis of pelubiprofen

References

^ "Pelubiprofen - Daewon Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
^ Chan-Hyuk K (26 September 2023). "Daewon Pharm wins $3 million deal to export Pelubi to Indonesia". Korea Biomedial Review.
^ "(Eperisone + pelubiprofen) by Daewon Pharmaceutical for Low Back Pain: Likelihood of Approval". pharmaceutical-technology.com. 5 June 2023.
^ Park JY, Oh DH, Park SW, Chae BR, Kim CW, Han SH, et al. (May 2021). "Development of Pelubiprofen Tromethamine with Improved Gastrointestinal Safety and Absorption". Pharmaceutics. 13 (5): 745. doi:10.3390/pharmaceutics13050745. PMC 8158122. PMID 34070062.
^ Serradell, MN; Castaer, J.; RS-2131. Drugs Fut 1984, 9, 4, 275.
^ Terada, Atsusuke; Naruto, Shunji; Wachi, Kazuyuki; Tanaka, Shigeru; Iizuka, Yoshio; Misaka, Eiichi (1984). "Synthesis and antiinflammatory activity of [(cycloalkylmethyl)phenyl]acetic acids and related compounds". Journal of Medicinal Chemistry. 27 (2): 212–216. doi:10.1021/jm00368a019.
^ Atsusuke Terada, Shigeru Tanaka, & Eiichi Misaka, US4254274 (1981 to Sankyo Co Ltd).
^ Yuan Weiguan, et al. CN111153791 (2020 to HUNAN JIUDIAN HONGYANG PHARMACEUTICAL Co., Ltd).
^ Yuan Weiguan, et al. WO2021129651 (to Hunan Jiudian Pharmaceutical Co Ltd).
^ Ning Hulin, et al. CN110041191 (2019 to HUNAN JIUDIAN HONGYANG PHARMACEUTICAL Co., Ltd.).
^ ChemDrug

[1] "Pelubiprofen - Daewon Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.

[2] Chan-Hyuk K (26 September 2023). "Daewon Pharm wins $3 million deal to export Pelubi to Indonesia". Korea Biomedial Review.

[3] "(Eperisone + pelubiprofen) by Daewon Pharmaceutical for Low Back Pain: Likelihood of Approval". pharmaceutical-technology.com. 5 June 2023.

[4] Park JY, Oh DH, Park SW, Chae BR, Kim CW, Han SH, et al. (May 2021). "Development of Pelubiprofen Tromethamine with Improved Gastrointestinal Safety and Absorption". Pharmaceutics. 13 (5): 745. doi:10.3390/pharmaceutics13050745. PMC 8158122. PMID 34070062.

[5] Serradell, MN; Castaer, J.; RS-2131. Drugs Fut 1984, 9, 4, 275.

[6] Terada, Atsusuke; Naruto, Shunji; Wachi, Kazuyuki; Tanaka, Shigeru; Iizuka, Yoshio; Misaka, Eiichi (1984). "Synthesis and antiinflammatory activity of [(cycloalkylmethyl)phenyl]acetic acids and related compounds". Journal of Medicinal Chemistry. 27 (2): 212–216. doi:10.1021/jm00368a019.

[7] Atsusuke Terada, Shigeru Tanaka, & Eiichi Misaka, US4254274 (1981 to Sankyo Co Ltd).

[8] Yuan Weiguan, et al. CN111153791 (2020 to HUNAN JIUDIAN HONGYANG PHARMACEUTICAL Co., Ltd).

[9] Yuan Weiguan, et al. WO2021129651 (to Hunan Jiudian Pharmaceutical Co Ltd).

[10] Ning Hulin, et al. CN110041191 (2019 to HUNAN JIUDIAN HONGYANG PHARMACEUTICAL Co., Ltd.).

[11] ChemDrug

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]